<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987855</url>
  </required_header>
  <id_info>
    <org_study_id>RSD-CRPS</org_study_id>
    <nct_id>NCT02987855</nct_id>
  </id_info>
  <brief_title>Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia</brief_title>
  <acronym>ADcSVF-CRPS</acronym>
  <official_title>Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), and Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healeon Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healeon Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and&#xD;
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.&#xD;
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system&#xD;
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and&#xD;
      disabilities. They are often associated with injury sites (including surgical) which produce&#xD;
      constant, often disabling pain and motor-sensory losses.&#xD;
&#xD;
      Treatments are often ineffective and include medications (often high dose opiates), Physical&#xD;
      Therapy (PT), and surgical interventions (sympathectomy, ablation) or insertion stimulators&#xD;
      of the CNS.&#xD;
&#xD;
      Study is an interventional study to document the safety and efficacy of use of&#xD;
      adipose-derived cellular stromal vascular fraction (AD-cSVF) in chronic pain and dysfunction&#xD;
      disease groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and&#xD;
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.&#xD;
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system&#xD;
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and&#xD;
      disabilities. They are often associated with injury sites (including surgical) which produce&#xD;
      constant, often disabling pain and motor-sensory losses.&#xD;
&#xD;
      Treatments are often ineffective and include medications (often high dose opiates), physical&#xD;
      therapy (PT(, and surgical interventions (sympathectomy, ablation) or insertion stimulators&#xD;
      of the CNS.&#xD;
&#xD;
      Clinical Features include neurogenic inflammation, nociceptive sensitization, vasomotor&#xD;
      dysfunction and maladaptive neuroplasticity. As these often seem related to specific injury&#xD;
      sites (trauma, surgical, etc.) which are followed with severe pain sensations such as&#xD;
      stabbing, burning, throbbing, and local muscular spasms or hemiparesis. In addition, there&#xD;
      are many reports of visual change, dropping attacks (sudden falling), joint soreness, and&#xD;
      other systemic symptoms associated with potentially any organ in the body.&#xD;
&#xD;
      Diagnosis typically recognizes 3 distinct &quot;types&quot; which do not appear to be sequential in&#xD;
      nature. Type 1 characterization is severe, burning sensory change near an injury site,&#xD;
      musculoskeletal and joint stiffness. Type 2 demonstrates very high pain levels, swelling,&#xD;
      muscular atrophy, joint degeneration, depression, and other concomitant dysfunctions. Type 3&#xD;
      features irreversible changes to skin/bone, and extreme loss of function of muscle (atrophic&#xD;
      primarily) and tendons. A significant percentage (13-70 ) are felt to be at risk if&#xD;
      neurological injuries, hemiplegia, enhanced vasomotor issues due to enhanced sympathetic&#xD;
      actions and neurotransmission issues.&#xD;
&#xD;
      This study includes microcannula harvesting of subdermal adipose tissues, incubation,&#xD;
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual&#xD;
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline&#xD;
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured&#xD;
      at intervals (both severe and non-severe categories) and by repeated pulmonary function&#xD;
      studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility&#xD;
    is being closed due to viral limitations and loss of staff to perform]&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse and Severe Adverse Reaction Report</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate any Adverse or Severe Adverse Reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Pain Levels</measure>
    <time_frame>1 month, 6 month, 1 year</time_frame>
    <description>Pain Scale Questionnaire 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life from Baseline</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Quality of Life Questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Lifestyle</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Fibromyalgia Impact Questionnaire (FIQR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>RSD (Reflex Sympathetic Dystrophy)</condition>
  <condition>CRPS - Complex Regional Pain Syndrome Type I</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline IV with AD-cSVF cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipoaspiration</intervention_name>
    <description>Closed syringe harvesting subdermal fat</description>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADcSVF isolation</intervention_name>
    <description>Isolation of AD-cSVF from lipoaspirate via enzymatic digestion</description>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline IV</intervention_name>
    <description>Normal Saline IV containing autologous AD-cSVF</description>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of RSD, CRPS, and severe Fibromyalgia&#xD;
&#xD;
          -  Ability to provide Informed Consent (or as parent or legal guardian)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe comorbidities which, in opinion of PI or provider associates.&#xD;
             would be unsafe or not advised to be able to comply with study or follow up&#xD;
             requirements&#xD;
&#xD;
          -  Patients with documented Opiate abuse&#xD;
&#xD;
          -  Patient taking corticosteroid therapy, immune suppression, or chemotherapeutic regimen&#xD;
             within 6 months of entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn C Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Alliance for Regenerative Medicine (GARM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regenevita LLC</name>
      <address>
        <city>Stevensville</city>
        <state>Montana</state>
        <zip>59870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GARM</name>
      <address>
        <city>Roatan</city>
        <state>Hn</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May;25(4):273-80. doi: 10.1097/AJP.0b013e31818ecea5.</citation>
    <PMID>19590474</PMID>
  </reference>
  <reference>
    <citation>Marinus J, Moseley GL, Birklein F, Baron R, Maihöfner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011 Jul;10(7):637-48. doi: 10.1016/S1474-4422(11)70106-5. Review.</citation>
    <PMID>21683929</PMID>
  </reference>
  <reference>
    <citation>Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23;342(8878):1012-6.</citation>
    <PMID>8105263</PMID>
  </reference>
  <reference>
    <citation>Maihöfner C, Forster C, Birklein F, Neundörfer B, Handwerker HO. Brain processing during mechanical hyperalgesia in complex regional pain syndrome: a functional MRI study. Pain. 2005 Mar;114(1-2):93-103. Epub 2005 Jan 26.</citation>
    <PMID>15733635</PMID>
  </reference>
  <reference>
    <citation>Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med. 2005 Feb;257(2):139-55. Review.</citation>
    <PMID>15656873</PMID>
  </reference>
  <reference>
    <citation>Birklein F. Complex regional pain syndrome. J Neurol. 2005 Feb;252(2):131-8. Review.</citation>
    <PMID>15729516</PMID>
  </reference>
  <reference>
    <citation>Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, Sullivan P, Meier P, Zurakowski D, Masek BJ, Berde CB. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002 Jul;141(1):135-40.</citation>
    <PMID>12091866</PMID>
  </reference>
  <reference>
    <citation>van de Meent H, Oerlemans M, Bruggeman A, Klomp F, van Dongen R, Oostendorp R, Frölke JP. Safety of &quot;pain exposure&quot; physical therapy in patients with complex regional pain syndrome type 1. Pain. 2011 Jun;152(6):1431-1438. doi: 10.1016/j.pain.2011.02.032. Epub 2011 Apr 6.</citation>
    <PMID>21474244</PMID>
  </reference>
  <reference>
    <citation>Swart CM, Stins JF, Beek PJ. Cortical changes in complex regional pain syndrome (CRPS). Eur J Pain. 2009 Oct;13(9):902-7. doi: 10.1016/j.ejpain.2008.11.010. Epub 2008 Dec 19. Review.</citation>
    <PMID>19101181</PMID>
  </reference>
  <reference>
    <citation>Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.</citation>
    <PMID>23546884</PMID>
  </reference>
  <reference>
    <citation>Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs. 2012 Mar 1;26(3):215-28. doi: 10.2165/11595200-000000000-00000. Review.</citation>
    <PMID>22136149</PMID>
  </reference>
  <reference>
    <citation>Opal SM, Wiest PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. R I Med J. 1990 May;73(5):199-204.</citation>
    <PMID>2343234</PMID>
  </reference>
  <reference>
    <citation>Varenna M, Adami S, Rossini M, Gatti D, Idolazzi L, Zucchi F, Malavolta N, Sinigaglia L. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2013 Mar;52(3):534-42. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30.</citation>
    <PMID>23204550</PMID>
  </reference>
  <reference>
    <citation>Gainer MJ. Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn. 1992 Apr;34(4):227-32.</citation>
    <PMID>1349789</PMID>
  </reference>
  <reference>
    <citation>Hamdi TN. The Copeland intraocular lens: five to ten years later. Ophthalmology. 1979 Jun;86(6):984-96.</citation>
    <PMID>534104</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>February 14, 2021</last_update_submitted>
  <last_update_submitted_qc>February 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healeon Medical Inc</investigator_affiliation>
    <investigator_full_name>Robert W. Alexander, MD, FICS</investigator_full_name>
    <investigator_title>Principal Investigator, Science</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

